


Cyclobutane Synthesis and Fragmentation. A Cascade Route to the *Lycopodium* Alkaloid (–)-Huperzine A

James D. White,* Yang Li, Jungchul Kim, and Miroslav Terinek

Department of Chemistry, Oregon State University, Corvallis, Oregon 97331, United States

S Supporting Information

ABSTRACT: An asymmetric total synthesis of the nootropic alkaloid (–)-huperzine A was completed using a cascade sequence initiated by an intramolecular aza-Prins reaction and terminated by a stereoelectronically guided fragmentation of a cyclobutylcarbiny cation as the key step in assembling the bicyclo[3.3.1]nonene core of the natural product. Intramolecular [2 + 2]-photocycloaddition of the crotyl ether of (S)-4-hydroxycyclohex-2-enone afforded a bicyclo[4.2.0]octanone containing an embedded tetrahydrofuran in which the cyclohexanone moiety was converted to a triisopropylsilyl enol ether and functionalized as an allylic azide. The derived primary amine was acylated with α -phenylselenenylacrylic acid, and the resulting amide was reacted with trimethylaluminum to give a [2 + 2]-cycloadduct, which underwent retroaldol fission to produce a fused α -phenylselenenyl δ -lactam. Periodate oxidation of this lactam led directly to an α -pyridone, which was converted to a fused 2-methoxypyridine. Reductive cleavage of the activated “pyridylic” C–O bond in this tetracycle and elaboration of the resultant hydroxy ketone to a diketone was followed by chemoselective conversion of the methyl ketone in this structure to an endo isopropenyl group. Condensation of the remaining ketone with methyl carbamate in the presence of acid initiated the programmed cascade sequence and furnished a known synthetic precursor to huperzine A. Subsequent demethylation of the carbamate and the methoxypyridine, accompanied by in situ decarboxylation of the intermediate carbamic acid, gave (–)-huperzine A.



INTRODUCTION

The seminal publications by Woodward and Hoffmann five decades ago that set forth “rules” governing, among other reactions, the addition of one alkene unit to another¹ have spawned a vast body of research on both the theoretical and synthetic implications of the [2 + 2]-cycloaddition process.² A rationale based on “orbital symmetry”, or more precisely upon orbital correlation diagrams that consider the relationship of HOMO and LUMO electronic states of reactants, explained that, while cycloaddition of two alkenes in their ground electronic states was thermally “forbidden”, the corresponding cycloaddition with one of the alkenes in an electronically excited state would be “allowed”. In the latter case, a cyclobutane would result, initially, in an electronically excited state, but relaxation to the ground state would follow.³ Deciding what “forbidden” actually means in energy terms is not always straightforward,⁴ but a practical consequence of the Woodward–Hoffmann paradigm is that extensive use has been made of photochemistry to excite an alkene in the presence of a second ground-state alkene to prepare cyclobutanes.⁵ An early application of this principle to the synthesis of a natural product (and one inspired by the insight brought to cycloaddition processes by Woodward himself during his legendary research group meetings of the 1960s) was our synthesis of the bourbonene sesquiterpenoids, where photocycloaddition of cyclopentenone to a substituted cyclopentene installed the central cyclobutane in these tricyclic structures.⁶

The ease with which cyclobutanes can be synthesized photochemically taken with the fact that the four-membered carbocycle contains ca. 26 kcal/mol of strain energy⁷ has led to a

rich portfolio of synthetic applications resulting from release of that ring strain.⁸ Examples include cycloreversion of a cyclobutane to form two new alkene units, a process employed in our synthesis of byssochlamic acid,⁹ ring expansion to a cyclopentane,¹⁰ and ring scission to generate new cyclic or acyclic entities possessing diminished strain relative to the starting cyclobutane.^{11,12} A cyclobutane cleavage pathway that can be characterized as a “downhill” progression in energy terms is the conceptual basis for our synthesis of the *Lycopodium* alkaloid huperzine A (1).¹³ Huperzine A, a constituent of the club moss *Huperzia serrata* (Thunb.), has attracted attention as a result of claims that the compound has restorative properties for cognitive impairment and has the ability to improve memory function. Historically, *H. serrata* has been used in China under the name Chien Tseng Ta to treat a variety of illnesses including Alzheimer’s dementia.¹⁴ Although huperzine A is easily accessible from its natural source and is often sold as a component of herbal remedies, the compound continues to be a target of opportunity among synthetic organic chemists.

The first synthesis of huperzine A as its racemate was completed by Kozikowski et al., who used a tandem Michael–aldol sequence to fabricate the bicyclo[3.3.1]nonene portion of the molecule.¹⁵ The route was subsequently improved by the Kozikowski group¹⁶ and then adapted to an asymmetric

Special Issue: 50 Years and Counting: The Woodward–Hoffmann Rules in the 21st Century

Received: July 29, 2015


Published: September 10, 2015

synthesis of natural (–)-huperzine A.¹⁷ A synthesis of racemic **1** almost identical to that of Kozikowski has been published by Ji and Qian.¹⁸ Kozikowski later developed a second route to **1** using a palladium-catalyzed bicycloannulation to construct the bicyclo[3.3.1]nonene core,¹⁹ and this strategy has been utilized by both Terashima et al. in a synthesis of (–)-**1**²⁰ and by Langlois et al. in a formal synthesis of (+)-**1**.²¹ Two recent syntheses of huperzine A using novel approaches, one by Fukuyama et al.²² and the other by Lin et al.,²³ have been reported.

RESULTS AND DISCUSSION

Our approach to **1** was based on the proposition that release of strain in a cyclobutane embedded within a structure such as **2** could be used to generate the less strained bicyclo[3.3.1]nonene framework of **1** (Scheme 1).²⁴ The event designed to release that


Scheme 1. Proposed Route to Huperzine A Using an Aza-Prins-cyclobutylcarbonyl Cation Fragmentation Cascade



strain would be fragmentation of bond “a” in cyclobutylcarbonyl cation **3**, the cation being formed via an intramolecular aza-Prins reaction²⁵ of **2**. While alternative fragmentation modes of the cyclobutane in **3** are certainly conceivable, the orbital alignment suggested by the arrows in Scheme 1 implies that a stereoelectronic bias should favor the fragmentation pathway we desire. The retrosynthetic direction from **2** envisioned construction of a bicyclo[4.2.0]octane precursor **4** via [2 + 2]-photocycloaddition of a cyclohexenone to a suitably functionalized alkene,²⁶ with the methoxypyridine unit in **2** being fused to this template in a subsequent operation. As it happened, a [2 + 2]-cycloaddition and fragmentation of the resultant cyclobutane also featured in the methoxypyridine annulation en route to **2**.


Our goal from the outset was an asymmetric synthesis of huperzine A in its natural absolute configuration, and it was recognized that a plausible way to achieve this would be to incorporate a stereogenic center in one of the photopartners, leading to **4**. Maximum stereocontrol would be assured if the photocycloaddition were intramolecular,²⁷ and a decision was made to link the two photoaddends through a functional group in the cyclohexenone partner. An attractive starting point based on this precept was (S)-(–)-4-hydroxycyclohex-2-enone (**5**), prepared from (–)-quinic acid by the method of Danishefsky.²⁸ However, our first approach to the bicyclooctane core of **4** via photocycloaddition of an unsaturated ester derived from **5** proved to be flawed since neither crotonate **6**, prepared from **5** and *trans*-crotonyl chloride, nor ester **7**, obtained from **5** with (*E*)-2-methyl-3-pentenoic acid, afforded any trace of cycloadducts **8** and **9** upon irradiation (Scheme 2). Instead, complex mixtures were produced in each case.

Scheme 2. Attempted Photocycloaddition of Unsaturated Esters of 4-Hydroxycyclohex-2-enone



While these failed sequences were disappointing, we were aware that previous studies by others²⁹ had shown that unsaturated ethers tethered to a photoreactive cyclic enone readily undergo intramolecular [2 + 2]-cycloaddition. For example, Garibaldi et al. reported that irradiation of 3-allyloxycyclopent-2-enone (**10**) gave tricyclic adduct **11** in high yield (Scheme 3).³⁰

Scheme 3. Intramolecular Photocycloaddition of 3-Allyloxycyclopent-2-enone



On the basis of this precedent, we used Martin's method³¹ to prepare crotyl ether **12** as a prospective photostubstrate by treatment of **5** with *trans*-crotyl bromide and silver(I) oxide. After exploratory studies to determine optimal reaction conditions, intramolecular [2 + 2]-adduct **13** was obtained in a consistent 55–60% yield upon irradiation of **12** through Pyrex glass with a 450 W medium pressure mercury lamp (Scheme 4). It was important to use degassed dichloromethane as solvent for this reaction, which was carried out at 0 °C and was generally complete within 2 h. Since four new stereocenters were generated in **13** from the single stereogenic carbon in **12**, verification of the configuration of **13** was undertaken using NOE experiments. The proton correlations shown in Figure 1 confirmed that cycloaddition of **12** had occurred in a *syn* sense at the cyclohexenone double bond and with preservation of the *trans* relationship originating in the crotyl appendage.

With **13** in hand, our next goal was fusion of a methoxypyridine unit to this bicyclic substrate. Our initial route envisioned introduction of a 2,3-double bond into **13**, then using the derived cyclohexenone **14** as a dienophile in a [4 + 2]-cycloaddition with a 1-azadiene.³² The transformation of **13** to cyclohexenone **14** was straightforward and involved α -selenylation with phenylselenenyl chloride, followed by *in situ*

Scheme 4. Intramolecular Photocycloaddition of (4S)-4-Crotyloxycyclohex-2-enone and Reductive C–O Cleavage of the Product




Figure 1. Nuclear Overhauser enhancement of irradiated proton signals in 13.


oxidation with sodium periodate.³³ Before testing 14 as a dienophile in an aza-Diels–Alder reaction, we took advantage of an opportunity to investigate reductive cleavage of the allylic C–O bond of the tetrahydrofuran since the resulting primary alcohol would be a logical platform for advance toward the endo isopropenyl group of 2. An extensive search for a suitable method to effect this reductive scission revealed that only Yadav's protocol³⁴ using zinc in refluxing ethanol was successful in producing 15, other reductants generally returning saturated ketone 13 as the major product. Oxidation of 15 to an aldehyde which would precede completion of a path to the isopropenyl substituent of 2 surprisingly afforded the intramolecular aldol product 16, a result that, in retrospect, could have been foreseen given the endo disposition of the transient aldehyde and its proximity to the β,γ -unsaturated ketone. Attempts to reverse the formation of 16 were unsuccessful, and installation of the isopropenyl group of 2 was deferred to a later step.

It was evident that formation 16 upon oxidation of 15 could have been avoided if a pyridine ring were fused to 13 so that enolization of the ketone was blocked. Attention, therefore, returned to enone 14 as a prospective dienophile partner for an aza-Diels–Alder reaction that would create a δ -lactam for eventual aromatization to a pyridine. In this scenario, the C–O bond for reductive cleavage would become pseudobenzylic, i.e., “pyridylic”, and consequently should be more susceptible toward fission than the corresponding C–O bond in 14. Unfortunately, 14 failed to react with any of a variety of 1-azadienes including those bearing methoxy substituents at C-2 and C-4 as well those carrying an activating *N*-dimethylamino substituent,³⁵ and it became apparent from these experiments that the combination of a weak dienophile with a 1-azadiene was an incompatible pairing for cycloaddition. This approach to annulation of

the pyridine moiety of 2 was, therefore, abandoned in favor of a stepwise plan.

The first step in our new route to 2 envisioned conjugate addition of azide to enone 14, but this reaction encountered the twin difficulties of facile reversibility and clean separation of an unstable product from starting material. As a result, we were unable to force the reaction to completion. A timely solution to this problem appeared in a publication from the Magnus laboratory which reported that treatment of a triisopropylsilyl enol ether with trimethylsilyl azide and iodosobenzene gave an allylic azide in good yield.³⁶ Application of the Magnus protocol to 13 first required preparation of silyl enol ether 17, which, after brief chromatographic purification, was exposed to iodosobenzene and trimethylsilyl azide at low temperature (Scheme 5).

Scheme 5. Synthesis of Acrylamide 20 from Photoadduct 13



The reaction afforded an excellent yield of azide 18 as a single stereoisomer whose *exo* configuration was proven by proton–proton coupling constants in its NMR spectrum (Figure 2).





Figure 2. Proton–proton coupling constants in azide 18.

Reduction of 18 with lithium aluminum hydride furnished primary amine 19, which was reacted in situ with acryloyl chloride to yield amide 20.

It was hoped that silyl enol ether 20 would undergo Lewis acid catalyzed intramolecular Mukaiyama–Narasaka conjugate addition³⁷ to generate δ -lactam 21, but hydrolysis of the silyl enol ether and subsequent β elimination of the acrylamide moiety intervened to regenerate 14. On the supposition that an α -bromo amide would provide a more compliant acceptor for ring closure, amine 19 was acylated with α -bromoacryloyl chloride to afford 22, but this bromo amide suffered the same fate as 20 when Narasaka cyclization was attempted. At this point, a second publication from the Magnus lab came to our attention in the form of a report describing intramolecular trimethylaluminum-catalyzed [2 + 2]-cycloaddition of acrylamide 23 to give 24 (Scheme 6).³⁸

The Magnus reaction conditions applied to 22 led smoothly to crystalline pentacyclic adduct 25 (Scheme 7). It is noteworthy that the configuration of the nine stereogenic carbons in the

Scheme 6. Magnus' Trimethylaluminum-Mediated [2 + 2]-Cycloaddition of Acrylamide 23




congested framework of **25** emanate from the single stereocenter in **5** and that **25** is quite stable despite the presence of ring strain associated with two embedded cyclobutanes. Although formally a [2 + 2]-cycloaddition, the transformation of **22** to **25** falls outside the scope of the Woodward–Hoffmann rules and is most likely a stepwise process involving zwitterionic intermediate **26**.


The β -silyloxy carbonyl motif contained within the δ -lactam portion of **25** set the stage for retroaldol fission of the new cyclobutane ring, and exposure of **25** to aqueous HF in nitromethane gave α -bromo lactams **27** and **28** in high yield as a 3:1 epimeric mixture (Scheme 8). In principle, base-mediated elimination of HBr from either of these δ -lactams should yield a dihydropyridone from which the methoxypyridine system of **2** could be obtained after aromatization. However, we had not foreseen that basic reaction conditions could also generate a ketone enolate from these keto lactams and that internal alkylation resulting in 1,3-elimination could occur.³⁹ In fact, exposure of the major bromo lactam **27** to DBU gave fused cyclopropane **29** as the only detectable product, and minor isomer **28** suffered the same fate.

The intramolecular alkylation that produced **29** was avoided by replacing the bromine atom in **22** with a selenium substituent so that formation of an α,β -unsaturated δ -lactam could be accomplished oxidatively rather than by treatment with base. This revision necessitated a return to azide **18**. Coupling of the primary amine from reduction of **18** with α -phenylselenylacrylic acid⁴⁰ in the presence of 3,5-dinitrobenzoyl chloride gave amide **30**, which, upon treatment with trimethylaluminum, afforded the expected [2 + 2]-cycloadduct **31** (Scheme 9). The latter underwent retroaldol fission with aqueous HF in nitromethane to give separable epimeric α -selenyl lactams **32** and **33** in an approximately 1:1 ratio. Exposure of **32** and **33** to sodium periodate revealed that the two α -selenyl lactams behaved differently. Whereas both **32** and **33** formed their respective selenoxides, only that from **33** underwent elimination. The failure of the selenoxide from **32** to give an unsaturated lactam is

Scheme 8. Retroaldol Fission of 25 and Elimination to Cyclopropane 29




Scheme 9. Trimethylaluminum-Mediated [2 + 2]-Cycloaddition of α -Phenylselenylacrylamide 30, Retroaldol Cleavage of 31, and Oxidation to Pyridone 34




attributed to an unfavorable steric interaction of the endo phenylselenyloxy substituent in this structure with the ketone carbonyl, which prevents correct alignment for a 1,2-syn elimination. Fortunately, a potential loss of material at this late

Scheme 7. Trimethylaluminum-Mediated [2 + 2]-Cycloaddition of Bromoacrylamide 22



stage was averted when the mixture of α -selenyl lactams was found to equilibrate in favor of **33** (10:1) with excess aqueous HF. A second fortuitous discovery was that reaction of **33** with excess sodium periodate led to fully unsaturated α -pyridone **34**. The dehydrogenation that occurs after elimination of the selenoxide from **33** to form a transient α,β -unsaturated δ -lactam is probably initiated by oxidation at the activated ring junction, but the precise mechanism of this transformation remains unknown. In any event, the foregoing results provided an efficient pathway from **31** to **34** involving exposure of **31** to 4 equiv of aqueous HF in nitromethane, followed directly by addition of excess sodium periodate to afford **34** in 83% overall

Scheme 10. Reductive Cleavage of **35 and Oxidation to Diketone **39****




yield. Pyridone **34** was converted uneventfully to methoxypyridine **35** with methyl iodide in the presence of silver(I) carbonate.

Reductive scission of the activated “pyridylic” C–O bond in **35** was expected to be more facile than cleavage of the analogous C–O bond in **14**, but this conjecture proved to be unfounded. Although hydrogenolysis of **35** using various palladium catalysts including Pearlman’s catalyst⁴¹ did produce a primary alcohol under forcing conditions, the reaction was always accompanied by reduction of the keto group. As with **14**, the only satisfactory reagent for effecting reductive cleavage of the C–O bond in **35** proved to be zinc.³⁴ Activation of zinc using Newman’s method⁴² and exposure of **35** to an excess of the metal in MeOH containing 0.2 M NaOH at reflux gave hydroxy ketone **36** in excellent yield with no detectable reduction of the carbonyl group (Scheme 10). Alcohol **36** was advanced to keto aldehyde **37** upon oxidation with Dess–Martin periodinane⁴³ and a chemoselective Grignard reaction⁴⁴ at the aldehyde of **37** with methylmagnesium bromide produced an inconsequential 1:1 mixture of epimeric hydroxy ketones **38**. Oxidation of the mixture, again with Dess–Martin periodinane,⁴³ yielded a single diketone **39**.

At this point, our blueprint called for differentiating the two ketones of **39** by converting the methyl ketone to the isopropenyl group of **2** while leaving the cyclohexanone carbonyl intact for later derivatization as an activated imine. It was reasoned that the cyclohexanone carbonyl of **39** should be relatively unreactive toward methylenating reagents by virtue of its “through conjugation” to the methoxy substituent on the pyridine ring. On the other hand, the endo orientation of the methyl ketone in **39** presents a “hidden” carbonyl to an external reagent that could also render this functional group unreactive. Predictably, attempts to effect selective methylenation of the methyl ketone of **39** using Peterson olefination,⁴⁵ Petasis–Tebbe methylenation,⁴⁶ or a Wittig reaction⁴⁷ met with little success and confirmed that chemoselectivity was difficult to achieve in this structural setting (Scheme 11). Wittig olefination of **39** with methylenetriphenylphosphorane did give a modest yield of **40**


Scheme 11. Attempted Methylenation of Diketone **39**



along with **41** and the bis methylenated product **42**, and a small bonus accrued from the finding that **41** could be ozonized efficiently to **39**, which could then be recycled. Nevertheless, acquisition of **40** from **39** using this late-stage strategy was an impractical means for advancing the synthesis toward **1**.

Selective methylenation at the sterically hindered methyl ketone of **39** was solved when it was recognized that this ketone, as distinct from the cyclohexanone carbonyl, was enolizable and that it cleanly formed enol triflate **43** in the presence of base and Comins' reagent⁴⁸ (Scheme 12). Subsequent reaction of **43** with


Scheme 12. Conversion of Diketone 39 to Isopropenyl Ketone 40 and Its Oxime 44



hexamethyldistannane and tetrakis(triphenylphosphine)-palladium(0) resulted in Stille cross-coupling⁴⁹ that replaced the triflate by a methyl group and gave **40** as a crystalline solid in an overall yield of 56% from **39**.

In contrast to its reluctant engagement with methylenating agents, the cyclohexanone carbonyl of **40** readily condensed with benzylamine and with hydroxylamine hydrochloride, in the latter case forming a mixture of syn and anti oximes **44** (Scheme 13).

Scheme 13. Conversion of Isopropenyl Ketone 40 to (–)-Huperzine A



The possibility that activation of the mixture of oximes through exposure to a Lewis acid such as TiCl_4 could trigger aza-Prins cyclization,²⁵ followed by the cyclobutane fragmentation envisioned in Scheme 1, was investigated briefly, but Beckmann rearrangement⁵⁰ of **44** to an expanded ϵ -lactam appeared to be the only outcome from these experiments.

A more attractive derivative of **40** for initiating the cascade sequence projected in Scheme 1 appeared to be imino ester **45** since Beckmann rearrangement would be avoided and the reaction cascade, if successful, would lead directly to known compound **46**, the penultimate intermediate in Kozikowski's synthesis of huperzine A.¹⁵ Ketone **40** was condensed with methyl carbamate in the presence of anhydrous *p*-toluenesulfonic acid in hot benzene, and although carbamate **45** could not be isolated, its formation was signaled by a color change of the reaction medium to yellow (Scheme 13). The color dissipated over several hours, and chromatographic purification of the resulting mixture of products afforded **46**, whose spectral data matched those published by Xia and Kozikowski.¹⁵ Although a mixture of (*E*) and (*Z*) isomers at the *exo*-ethylidene substituent of **46** could have been anticipated from **45**, Kozikowski showed in the course of his synthetic work that the mixture equilibrates under acidic conditions to yield the thermodynamically favored (*E*) isomer.

Completion of our synthesis of (–)-**1** followed Kozikowski's route¹⁵ and involved treatment of **46** with trimethylsilyl iodide in chloroform. This reagent caused demethylation of both the methoxypyridine and the methyl carbamate along with concomitant decarboxylation of the intermediate carbamic acid and furnished material identical with natural (–)-huperzine A. Further confirmation that the structure of **46** from **40** had been correctly assigned was obtained by reacting a sample of natural (–)-huperzine A with methyl chloroformate in the presence of potassium carbonate and then treating the resulting urethane with methyl iodide and silver(I) carbonate to yield methoxypyridine **46**.

CONCLUSION

Although shorter pathways to huperzine A than the synthesis described here have appeared,^{15–23} our route demonstrates that ring strain inherent in a cyclobutane can be used to advantage in a molecular environment where that strain can be released in a controlled fashion. The exercise of predicting which of two or more ring cleavage modes will prevail in a particular structural setting is not always easy, but as illustrated in the present work, stereoelectronic factors can guide ring scission toward a preferred reaction pathway. Taken with other ring-opening reactions of cyclobutanes, such as cycloreversion (“[2-2]”),⁹ de Mayo-type retroaldol fission,¹¹ and retro-Mannich fragmentation,¹² it is clear that the four-membered carbocycle offers a valuable resource for the synthesis of natural and non-natural products.

EXPERIMENTAL SECTION

General Techniques. All reactions requiring anhydrous conditions were conducted in flame-dried glass apparatus under an atmosphere of argon. THF, Et_2O , CH_2Cl_2 , DMF, benzene, and acetonitrile were dried by passage through an activated alumina column under argon. DMSO was distilled from CaH_2 at 15 mmHg and stored over activated 4 Å molecular sieves. Anhydrous MeOH was freshly distilled from CaH_2 . Preparative chromatographic separations were performed on silica gel (35–75 μm); reactions were followed by TLC analysis using silica plates with a fluorescent indicator (254 nm) and visualized with a UV lamp or phosphomolybdic acid. Reactions were performed at various scales depending upon availability of the starting material and reflect the practical limitation that reactions in a lengthy synthetic sequence must be carried out many times, often by different individuals. Melting points were measured on a capillary melting point apparatus. Optical rotations were measured with a polarimeter at ambient temperature using a 1 mL capacity cell with a 1 dm path length. Infrared (IR) spectra were recorded using a thin film supported on KBr discs or dispersed in a KBr

pellet. ^1H and ^{13}C NMR spectra were recorded in Fourier transform mode at the field strength specified on a 300, 400, or 700 MHz spectrometer. Spectra were obtained on CDCl_3 solutions in 5 mm diameter tubes, and chemical shifts in ppm (part per million) are quoted relative to the residual signals of chloroform (δ_{H} 7.26 ppm, or δ_{C} 77.0 ppm). Multiplicities in the ^1H NMR spectra are described as s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad; coupling constants (J) are reported in Hz. Low (MS) and high (HRMS) resolution mass spectra were measured at 70 eV using a quadrupole analyzer and are reported with ion mass/charge (m/z) ratios as values in atomic mass units.

4-Oxocyclohex-2-en-1-yl (*E*)-But-2-enoate (6). To a solution of AgCN (35 mg, 0.27 mmol) and 4-hydroxycyclohex-2-en-1-one (30 mg, 0.27 mmol) in benzene (2 mL) at room temperature was added *trans*-crotonyl chloride (31 mg, 0.29 mmol). The mixture was stirred for 2 h at room temperature and was heated for 6 h at 80 °C. After cooling to room temperature, the mixture was diluted with Et_2O (20 mL), washed with 10% aqueous NaHCO_3 , and dried over anhydrous MgSO_4 . The solvent was removed under vacuum and the residue was chromatographed on silica, using 10% EtOAc in hexane as eluent, to give 37 mg (77%) of **6** as a colorless oil: IR (neat) 2961, 1718, 1687, 1257, 1102 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.9 (dd, J = 1.2, 7.1 Hz, 3H), 2.0–2.2 (m, 1H), 2.3–2.5 (m, 2H), 2.6 (m, 1H), 5.6 (m, 1H), 5.8–5.9 (dq, J = 1.7, 15.4 Hz, 1H), 6.0–6.1 (m, 1H), 6.8–6.9 (ddd, J = 1.6, 2.7, 10.5 Hz, 1H), 6.9–7.1 (dq, J = 7.1, 15.4 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 18.0, 28.7, 34.9, 67.3, 122.0, 130.7, 146.0, 147.8, 165.5, 197.9.

4-Oxocyclohex-2-en-1-yl (*E*)-2-Methylpent-3-enoate (7). To a solution of (*E*)-2-methyl-3-pentenoic acid (0.10 g, 0.93 mmol) and 4-hydroxycyclohex-2-en-1-one (0.10 g, 0.85 mmol) in Et_2O (2 mL) at room temperature was added sequentially DCC (0.19 g, 0.93 mmol) and DMAP (0.01 g, 0.09 mmol). The mixture was stirred for 4 h at room temperature, and the precipitated *N,N*-dicyclohexylurea was filtered off. The filtrate was washed with water (3 \times 1 mL), aqueous 5% AcOH (3 \times 1 mL), and water (3 \times 1 mL) and was dried over anhydrous MgSO_4 . The solvent was removed under vacuum and the residue was chromatographed on silica, using 25% EtOAc in hexane as eluent, to give 0.14 g (81%) of **7** as a mixture of two diastereomers: IR (neat) 2934, 1735, 1692, 1246, 1165, 1138 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.25 (d, J = 7.0 Hz, 3H), 1.69 (dd, J = 2.1, 7.1 Hz, 3H), 2.09 (m, 1H), 2.35 (m, 2H), 2.47 (m, 1H), 2.60 (m, 1H), 3.48 (m, 1H), 5.40 (m, 1H), 5.59 (m, 2H), 6.05 (m, 1H), 6.83 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 13.0, 17.5, 28.4, 28.5, 34.8, 37.7, 67.4, 67.5, 126.5, 128.9, 130.7, 130.8, 147.4, 147.5, 174.2, 197.8.

(*S,E*)-4-(But-2-en-1-yloxy)cyclohex-2-en-1-one (12). To a solution of 4-hydroxycyclohex-2-en-1-one (0.33 g, 2.94 mmol) in *trans*-crotyl bromide (2.5 mL) at 0 °C was added silver(I) oxide (1.7 g, 7.36 mmol) in several portions. The mixture was stirred for 6 h at room temperature, after which the excess silver(I) oxide was filtered off and excess crotyl bromide was removed under reduced pressure. The residue was chromatographed on silica, using 15% EtOAc in hexane as eluent, to give 0.81 g (59%) of **12** as a colorless oil: $[\alpha]_{\text{D}}^{25}$ –122 (c 1.51, CHCl_3); IR (neat) 2946, 2851, 1686, 1251, 1094, 968 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.74 (dd, J = 1.2, 6.8 Hz, 3H), 1.91–2.05 (m, 1H), 2.28–2.40 (m, 2H), 2.53–2.65 (m, 1H), 3.98 (m, 2H), 4.20 (m, 1H), 5.53–5.65 (dtq, J = 1.2, 6.7, 15.4 Hz, 1H), 5.67–5.85 (dtq, J = 1.3, 6.8, 15.3 Hz, 1H), 5.98 (m, 1H), 6.97 (ddd, J = 2.2, 3.2, 10.8 Hz, 1H), 5.21 (s, 2H), 5.27 (d, J = 13.6 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 17.7, 29.1, 35.2, 72.0, 127.0, 129.5, 130.2, 150.7, 198.7; MS (CI) m/z 167 (M + H), 149, 141, 123, 113; HRMS (CI) m/z 167.1066 (calcd for $\text{C}_{10}\text{H}_{15}\text{O}_2$: 167.1072).

(2a*R*,2a'*1R*,3*R*,3a*S*,6a*S*)-3-Methylhexahydro-2*H*-cyclobuta[*cd*]benzofuran-4(2*aH*)-one (13). A Pyrex photolysis apparatus was charged with a solution of **12** (0.91 g, 5.48 mmol) in CH_2Cl_2 (300 mL), and argon was passed through the solution for 2 h. The solution was cooled to 0 °C and irradiated with a 450 W medium-pressure mercury lamp for 2 h, after which the solvent was evaporated under reduced pressure. The residue was chromatographed on silica, using 15% EtOAc in hexane as eluent, to give 0.52 g (58%) of **13**: $[\alpha]_{\text{D}}^{25}$ + 238 (c 2.3, CHCl_3); IR (neat) 2954, 2925, 2861, 1697, 1175, 1057, 1013 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.19 (d, J = 7.1 Hz, 3H), 1.91 (ddd, J = 2.3,

4.6, 14.2, 14.3 Hz, 1H), 2.08–2.28 (m, 2H), 2.39–2.50 (m, 2H), 2.58 (m, 1H), 2.85–2.95 (ddd, J = 8.6, 14.2, 15.8 Hz, 1H), 3.02 (q, J = 8.8 Hz, 1H), 3.57 (dd, J = 4.5, 9.0 Hz, 1H), 3.85 (d, J = 9.1 Hz, 1H), 3.98 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 21.5, 27.4, 32.7, 37.8, 39.2, 45.4, 47.8, 72.5, 74.0, 211.7; MS (CI) m/z 167 (M + H), 157, 149, 141, 137, 123, 113, 95; HRMS (CI) m/z 167.0992 (calcd for $\text{C}_{10}\text{H}_{15}\text{O}_2$: 167.0994).

(2a*R*,2a'*1R*,3*R*,3a*S*,6a*S*)-3-Methyl-2a'*1,3,3a,6a*-tetrahydro-2*H*-cyclobuta[*cd*]benzofuran-4(2*aH*)-one (14). To a solution of **13** (20 mg, 0.12 mmol) in EtOAc (4 mL) was added phenylselenenyl chloride (35 mg, 0.18 mmol), and the mixture was stirred for 1 h at room temperature. The mixture was washed with saturated aqueous NaHCO_3 (1 mL) and saturated aqueous NaCl (1 mL) and was concentrated under reduced pressure. The residue was dissolved in THF (4 mL) and water (2 mL), and the solution was treated with NaIO_4 (77 mg, 0.36 mmol). The mixture was stirred for 3 h at room temperature and was poured into a mixture of Et_2O (10 mL) and water (5 mL). The organic phase was separated, the aqueous phase was extracted with EtOAc (3 \times 10 mL), and the combined organic extract was washed with brine and dried over anhydrous MgSO_4 . The solvent was removed under vacuum and the residue was chromatographed on silica, using 15% EtOAc in hexane as eluent, to give 16 mg (81%) of **14** as a colorless oil: $[\alpha]_{\text{D}}^{25}$ + 175 (c 1.0, CHCl_3); IR (neat) 2955, 2924, 2862, 1668, 1044 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 1.27 (d, J = 7.0 Hz, 3H), 2.31 (m, 1H), 2.58 (dd, J = 8.4, 8.5 Hz, 1H), 2.70 (m, 1H), 3.17 (ddd, J = 8.2, 8.2, 8.4 Hz, 1H), 3.59 (dd, J = 4.7, 9.8 Hz, 1H), 3.80 (d, J = 9.7 Hz, 1H), 4.38 (dd, J = 5.1, 8.3 Hz, 1H), 6.15 (d, J = 10.0 Hz, 1H) 7.08 (dd, J = 5.2, 10.1 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 21.0, 37.4, 39.4, 44.2, 46.0, 70.4, 71.1, 131.6, 144.7, 198.0; MS (CI) m/z 165 (M + H), 147, 139, 135, 111, 95; HRMS (CI) m/z 165.0915 (calcd for $\text{C}_{10}\text{H}_{13}\text{O}_2$: 165.0916).

7-Hydroxymethyl-8-methylbicyclo[4.2.0]oct-4-en-2-one (15). To a solution of Zn-Cu dust (98 mg) in dry EtOH (3 mL) was added a solution of **13** (49 mg, 0.12 mmol) in dry EtOH (1 mL) under argon, and the mixture was refluxed for 10 h. The solution was cooled to room temperature and filtered, and the filtrate was concentrated under vacuum. The residue was chromatographed on silica, using 30% EtOAc in hexane as eluent, to give 26 mg (52%) of **15** as a colorless oil: IR (neat) 3419, 2920, 2862, 1699, 1257, 1020 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.19 (d, J = 6.7 Hz, 3H), 2.20–2.43 (m, 1H), 2.64 (m, 1H), 2.81–2.90 (m, 1H), 3.00–3.14 (m, 1H), 3.29–3.38 (m, 1H), 3.65–3.71 (m, 1H), 5.88 (s, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 22.3, 36.9, 37.0, 37.4, 47.6, 49.7, 62.8, 124.6, 125.9, 208.2.

9-Hydroxy-8-methyltricyclo[3.3.1.0^{2,7}]non-3-en-6-one (16). To a solution of **15** (14 mg, 0.082 mmol) in CH_2Cl_2 (3 mL) was added Dess–Martin periodinane (52 mg, 0.123 mmol), and the mixture was stirred for 1.5 h at room temperature. The solution was diluted with Et_2O (5 mL), aqueous 10% $\text{Na}_2\text{S}_2\text{O}_3$ (2 mL) was added, and the mixture was stirred for 20 min. The solution was washed with brine (5 mL) and was extracted with Et_2O (2 \times 20 mL). The extract was dried over anhydrous MgSO_4 , the solvent was removed under vacuum, and the residue was chromatographed on silica, using 15% EtOAc in hexane as eluent, to give 9 mg (67%) of **16** as a colorless oil: IR (neat) 3409, 2959, 1719, 1073 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.48 (d, J = 7.0 Hz, 3H), 2.42 (m, 2H), 2.57 (m, 1H), 3.25 (m, 1H), 3.62 (m, 1H), 4.04 (m, 1H), 6.19 (m, 1H), 6.32 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 17.5, 33.8, 38.3, 41.9, 51.3, 58.5, 73.8, 131.6, 132.6, 209.9.

((2a*R*,2a'*1R*,3*R*,3a*S*,6a*R*)-6-Azido-3-methyl-2a'*1,3,3a,6a*-hexahydro-2*H*-cyclobuta[*cd*]benzofuran-4-yl)-oxy)trisopropylsilane (18). To a solution of **13** (0.20 g, 1.20 mmol) and TIPSCl (0.31 mL, 1.44 mmol) in THF (5 mL) at 0 °C was added slowly KHMDS (2.9 mL, 0.5 M solution in toluene, 1.44 mmol), and the solution was stirred for 30 min at room temperature. The solution was diluted with Et_2O (20 mL), washed with water and brine, and dried over MgSO_4 . The solvent was removed under vacuum and the residue was chromatographed on silica, using 20% EtOAc in hexane as eluent, to give crude silyl enol ether **17**. This material was dissolved in CH_2Cl_2 (10 mL), and iodosobenzene (0.32 g, 1.44 mmol) was added to the solution. The resulting suspension was cooled to –19 °C, trimethylsilyl azide (**Caution!** This compound can generate explosive hydrazoic acid;

0.38 mL, 2.89 mmol) was added, and the mixture was stirred at -19°C for 45 min, at which point the suspension had become a colorless solution. The mixture was allowed to warm to room temperature, the solvent was removed under vacuum, and the residue was filtered and washed with a 1:1 mixture of Et_2O (30 mL) and hexane (30 mL). The filtrate was concentrated under vacuum and the residue was chromatographed on silica, using 4% EtOAc in hexane as eluent, to give 0.32 g (73%) of **18** as a colorless oil: $[\alpha]_{\text{D}}^{25} -110$ (c 1.2, CHCl_3); IR (neat) 2946, 2866, 2099, 1649, 1377, 1228, 1199 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.05 (dd, $J = 2.2, 7.1$ Hz, 18H), 1.12–1.28 (m, 3H), 1.22 (d, $J = 7.0$ Hz, 3H), 1.90 (m, 1H), 2.29 (dd, $J = 6.6, 8.3$ Hz, 1H), 2.49 (ddd, $J = 5.1, 5.2, 8.3$ Hz, 1H), 3.08 (ddd, $J = 6.7, 8.4, 8.7$ Hz, 1H), 3.51 (dd, $J = 5.0, 9.2$ Hz, 1H), 3.75 (d, $J = 9.5$ Hz, 1H), 3.79 (dd, $J = 3.1, 6.6$ Hz, 1H), 4.20 (dd, $J = 2.2, 6.7$ Hz, 1H), 4.83 (d, $J = 6.7$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 12.5 (3C), 17.9 (7C), 21.8, 34.5, 38.6, 40.0, 44.4, 58.7, 72.6, 93.9, 157.8; MS (CI) m/z 364 (M + H), 321, 266, 165, 157, 131; HRMS (CI) m/z 364.2419 (calcd for $\text{C}_{19}\text{H}_{34}\text{N}_3\text{O}_2\text{Si}$: 364.2402).

N-(3-Methyl-4-((triisopropylsilyl)oxy)-2a,2a',3,3a,6,6a-hexahydro-2H-cyclobuta[cd]benzofuran-6-yl)acrylamide (20). To a solution of **18** (0.26 g, 0.74 mmol) in Et_2O (6 mL) at 0°C was added LiAlH_4 (41 mg, 1.09 mmol), and the suspension was stirred for 1 h. The mixture was diluted with Et_2O , and the reaction was quenched with 15% aqueous NaOH (0.078 mL). The mixture was stirred with MgSO_4 (2.63 g) for 2 h, then was filtered, and the collected solid was washed with EtOAc . Removal of the solvent under vacuum left crude amine **19** (0.24 g). To a solution of the crude amine and Et_3N (0.12 mL, 0.87 mmol) in Et_2O (6 mL) at 0°C was added acryloyl chloride (0.076 mL, 0.94 mmol), and the solution was stirred for 1 h. The mixture was diluted with Et_2O (30 mL), washed with aqueous 0.1 N HCl and brine, and dried over MgSO_4 . The solvent was removed under vacuum and the residue was chromatographed on silica, using 5% MeOH in CH_2Cl_2 as eluent, to give 0.24 g (84%) of **20** as a colorless oil: IR (neat) 3273 (br), 2944, 2865, 1655, 1532, 1223, 1196 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 1.08 (dd, $J = 3.4, 7.0$ Hz, 18H), 1.10–1.23 (m, 3H), 1.20 (d, $J = 7.0$ Hz, 3H), 1.92 (m, 1H), 2.20 (dd, $J = 6.9, 9.2$ Hz, 1H), 2.43 (m, 1H), 2.96 (m, 1H), 3.48 (dd, $J = 5.2, 9.1$ Hz, 1H), 3.78 (d, $J = 9.1$ Hz, 1H), 3.82 (dd, $J = 2.2, 6.9$ Hz, 1H), 4.79 (d, $J = 6.2$ Hz, 2H), 4.90 (m, 1H), 5.15 (m, 1H), 5.62 (dd, $J = 1.1, 10.0$ Hz, 1H), 6.01 (dd, $J = 10.0, 17.2$ Hz, 1H), 6.25 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 12.6 (3C), 17.9 (6C), 21.9, 33.9, 38.2, 40.0, 44.4, 47.2, 72.6, 76.3, 97.3, 126.4, 130.8, 155.7, 164.3; HRMS (CI) m/z 392.2622 (calcd for $\text{C}_{22}\text{H}_{38}\text{NO}_3\text{Si}$: 392.2621).

2-Bromo-N-((2aR,2a',3R,3aS,6R,6aR)-3-methyl-4-((triisopropylsilyl)oxy)-2a,2a',3,3a,6,6a-hexahydro-2H-cyclobuta[cd]benzofuran-6-yl)acrylamide (22). To a solution of **18** (0.263 g, 0.742 mmol) in Et_2O (7 mL) at 0°C was added LiAlH_4 (0.041 g, 1.09 mmol), and the suspension was stirred for 1 h. The mixture was diluted with Et_2O , and the reaction was quenched with 15% aqueous NaOH (0.078 mL). The mixture was stirred with MgSO_4 (2.63 g) for 2 h, then was filtered, and the collected solid was washed with EtOAc . Removal of the solvent under vacuum left virtually pure **19** (0.24 g). In a separate flask, a solution of 2-bromoacrylic acid (0.44 g, 2.90 mmol), oxalyl chloride (0.76 mL, 8.69 mmol), and a catalytic amount of DMF in CH_2Cl_2 (5 mL) was stirred at room temperature for 12 h. The solvent was removed in vacuo, and the resulting α -bromoacryloyl chloride was added to a solution of **19**, prepared above, and Et_3N (0.30 mL, 2.17 mmol) in Et_2O (8 mL) at 0°C . The solution was stirred for 1 h at 0°C and diluted with Et_2O (30 mL). The solution was washed with aqueous 0.1 N HCl and brine, dried over MgSO_4 , and concentrated under vacuum to leave a residue, which was chromatographed on silica, using 13% EtOAc in hexane as eluent, to give 0.22 g (59%) of **22** as a colorless oil: IR (neat) 3325 (br), 2943, 2864, 1657, 1495, 1223, 1196 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 1.08 (dd, $J = 3.4, 7.0$ Hz, 18H), 1.12–1.21 (m, 3H), 1.20 (d, $J = 7.0$ Hz, 3H), 1.92 (m, 1H), 2.23 (dd, $J = 6.9, 9.2$ Hz, 1H), 2.47 (ddd, $J = 5.3, 5.8, 8.4$ Hz, 1H), 2.99 (m, 1H), 3.49 (dd, $J = 5.2, 9.1$ Hz, 1H), 3.78 (d, $J = 9.1$ Hz, 1H), 3.82 (dd, $J = 2.2, 6.9$ Hz, 1H), 4.81 (m, 2H), 6.00 (d, $J = 1.2$ Hz, 1H), 6.22 (br d, $J = 6.8$ Hz, 1H), 7.00 (d, $J = 1.1$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 12.5 (3C), 17.9 (6C), 21.9, 33.9, 38.2, 40.0, 44.4, 48.3, 72.7, 75.9, 97.0, 122.7, 127.5, 156.3, 159.8; MS (CI) m/z 470 (M + H), 428, 400, 392,

321, 193, 165, 157; HRMS (CI) m/z 470.1728 (calcd for $\text{C}_{22}\text{H}_{37}\text{BrNO}_3\text{Si}$: 470.1726).

(1R,1aR,1a',3aR,4aR,6R,6bS)-6-Bromo-1-methyl-6a-((triisopropylsilyl)oxy)decahydro-1H-4,6-(epiminomethano)dicyclobuta[cd,f]benzofuran-7-one (25). To a solution of **22** (11 mg, 0.021 mmol) in CH_2Cl_2 (2 mL) was added Me_3Al (0.027 mL, 2 M in hexane, 0.027 mmol), and the solution was stirred at 70°C for 24 h. The solution was diluted with EtOAc (10 mL), washed with aqueous NaHCO_3 (0.5 mL) and brine, and dried over MgSO_4 . The solvent was removed under vacuum and the residue was chromatographed on silica, using 50% EtOAc in hexane as eluent, to give 7.6 mg (76%) of **25** as a pale yellow solid: IR (neat) 3296 (br), 2944, 2925, 2866, 1689, 1459, 1195, 1127 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.13–1.23 (m, 21H), 1.12 (d, $J = 7.1$ Hz, 3H), 1.79 (dd, $J = 6.6, 9.0$ Hz, 1H), 2.19 (m, 1H), 2.20 (ddd, $J = 5.4, 5.6, 8.7$ Hz, 1H), 2.29 (d, $J = 9.0$ Hz, 1H), 2.85 (m, 1H), 3.00 (dd, $J = 7.1, 9.0$ Hz, 1H), 3.10 (ddd, $J = 1.2, 5.5, 7.0$ Hz, 1H), 3.69 (dd, $J = 5.4, 9.1$ Hz, 1H), 3.90 (dd, $J = 6.8, 6.9$ Hz, 1H), 3.92 (d, $J = 9.2$ Hz, 1H), 4.09 (m, 1H), 6.11 (br, s, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 12.5 (3C), 18.5 (Si^iPr), 18.6 (Si^iPr), 22.4, 33.9, 36.2, 36.9, 37.9, 38.4, 41.2, 50.9, 69.0, 75.9, 77.9, 81.4, 172.6; MS (CI) m/z 470 (M + H), 428, 406, 390, 362, 321, 250, 232; HRMS (CI) m/z 469.1638 (calcd for $\text{C}_{22}\text{H}_{36}\text{BrNO}_3\text{Si}$: 469.1648).

(2aR,2a',3R,3aS,4aS,8aR,8bR)-6-Bromo-3-methyloctahydro-2H-cyclobuta[3,4]benzofuro[7,6-b]pyridine-4,7-(2aH,2a'H)-dione (27 and 28). To a solution of **25** (195 mg, 0.415 mmol) in MeNO_2 (20 mL) was added aqueous HF (48%, 1 mL), and the solution was stirred for 2 h. The mixture was diluted with EtOAc (50 mL), washed with aqueous NaHCO_3 (10 mL) and brine, and dried over MgSO_4 . The solvent was removed under vacuum, and the residue was chromatographed on silica, using 90% EtOAc in hexane and 1% MeOH in EtOAc as eluent, to give 83 mg (64%) of **27** as a colorless oil and 29 mg (22%) of **28** as a colorless oil. **27**: IR (neat) 3193 (br), 3062 (br), 2950, 2916, 2862, 1676, 942 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.27 (d, $J = 7.1$ Hz, 3H), 2.20 (m, 1H), 2.48–2.60 (m, 2H), 2.71 (dd, $J = 6.8, 9.4$ Hz, 1H), 2.95 (m, 1H), 3.09 (ddd, $J = 4.0, 4.1, 15.3$ Hz, 1H), 3.38 (m, 1H), 3.66 (dd, $J = 5.2, 9.3$ Hz, 1H), 3.87 (dd, $J = 4.0, 6.7$ Hz, 1H), 3.95 (d, $J = 9.4$ Hz, 1H), 4.38 (dd, $J = 4.1, 5.1$ Hz, 1H), 4.48 (dd, $J = 4.0, 6.9$ Hz, 1H), 6.43 (br s, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 21.7, 31.2, 36.9, 38.6, 39.6, 41.1, 44.2, 45.4, 54.2, 73.8, 76.1, 169.3, 210.6; MS (CI) m/z 314 (M + H), 276, 264, 236, 166; HRMS (CI) m/z 314.0393 (calcd for $\text{C}_{13}\text{H}_{17}\text{BrNO}_3$: 314.0392). **28**: IR (neat) 3210 (br), 3085 (br), 2953, 2923, 2863, 1681, 1270, 1179, 1109 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.21 (d, $J = 7.1$ Hz, 3H), 2.10–2.30 (m, 2H), 2.55 (dd, $J = 8.8, 8.9$ Hz, 1H), 2.68 (m, 1H), 3.18 (m, 3H), 3.62 (dd, $J = 4.2, 10.6$ Hz, 1H), 3.90 (d, $J = 10.6$ Hz, 1H), 3.91 (m, 1H), 4.47 (dd, $J = 3.3, 3.4$ Hz, 1H), 4.53 (dd, $J = 7.0, 10.7$ Hz, 1H), 6.53 (br, s, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 21.0, 32.6, 37.1, 37.7, 40.8, 41.1, 44.6, 46.7, 56.8, 72.7, 75.8, 168.9, 208.5; MS (CI) m/z 314 (M + H), 276, 264, 250, 236, 166; HRMS (CI) m/z 314.0390 (calcd $\text{C}_{13}\text{H}_{17}\text{BrNO}_3$: 314.0392).

(2aR,2a',3R,3aS,4aS,5aS,7aR,7bR)-3-Methyloctahydro-cyclobuta[3,4]benzofuro[7,6-b]cyclopropa[c]pyrrole-4,6-(2a'H,7bH)-dione (29). To a solution of the mixture of **27** and **28** (3 mg, 0.011 mmol) in toluene (4 mL) was added DBU (0.0043 mL, 0.029 mmol), and the solution was refluxed for 4 h. The cooled solution was diluted with Et_2O (10 mL), washed with brine, and dried over MgSO_4 . The solvent was removed under vacuum and the residue was chromatographed on silica, using 80% EtOAc in hexane and 1% MeOH in EtOAc as eluent, to give 1 mg (43%) of **29** as a colorless oil: IR (neat) 2920, 2847, 1699, 1459, 1406, 1064 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.13 (dd, $J = 5.2, 5.2$ Hz, 1H), 1.25 (d, $J = 7.0$ Hz, 3H), 1.91 (dd, $J = 4.3, 9.3$ Hz, 1H), 2.19 (dd, $J = 5.1, 9.4$ Hz, 1H), 2.30 (m, 1H), 2.51 (dd, $J = 6.9, 9.2$ Hz, 1H), 3.59 (ddd, $J = 5.1, 5.3, 7.1$ Hz, 1H), 3.48 (m, 1H), 3.57 (dd, $J = 5.0, 9.2$ Hz, 1H), 3.78 (d, $J = 5.2$ Hz, 1H), 3.90 (d, $J = 9.3$ Hz, 1H), 4.29 (s, 1H), 5.65 (br, s, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 17.2, 21.8, 30.0, 35.5, 36.7, 38.4, 44.9, 45.4, 58.9, 73.3, 77.6, 174.5, 206.1; MS (CI) m/z 234 (M + H), 180, 164; HRMS (CI) m/z 234.1125 (calcd for $\text{C}_{13}\text{H}_{16}\text{NO}_3$: 234.1130).

N-((2aR,2a',3R,3aS,6R,6aR)-3-Methyl-4-((triisopropylsilyl)oxy)-2a,2a',3,3a,6,6a-hexahydro-2H-cyclobuta[cd]benzofuran-6-yl)-2-(phenylselenenyl)acrylamide (30). To a solution of **18** (29 mg, 0.078 mmol) in Et_2O (1 mL) at 0°C was added LiAlH_4 (5 mg,

0.117 mmol), and the suspension was stirred for 1 h. The mixture was diluted with Et₂O, and the reaction was quenched with 15% aqueous NaOH (0.017 mL). The mixture was stirred with MgSO₄ (0.5 g) for 2 h, then was filtered, and the collected solid was washed with EtOAc. The solvent was removed under vacuum to leave crude **19**. In a separate flask, a solution of 3,5-dinitrobenzoyl chloride (37 mg, 0.163 mmol) and Et₃N (0.045 mL, 0.325 mmol) in CH₂Cl₂ (1 mL) was prepared, and a solution of α -phenylselenoacrylic acid (37 mg, 0.163 mmol) in CH₂Cl₂ (1 mL) was added. The mixture was stirred for 1 h at room temperature, a solution of crude **19** prepared above and DMAP (1 mg, 0.008 mmol) in CH₂Cl₂ (0.5 mL) was added, and the mixture was stirred for 1 h. The solvent was removed under vacuum and the residue was chromatographed on silica, using 15% EtOAc in hexane as eluent, to give 30 mg (69%) of **30** as a colorless oil: $[\alpha]_D^{25}$ -0.47 (c 1.51, CHCl₃); IR (neat) 3395 (br), 2944, 2864, 1655, 1649, 1491, 1477, 1223, 1196; ¹H NMR (300 MHz, CDCl₃) δ 1.00–1.15 (m, 21H), 1.17 (d, *J* = 7.0 Hz, 3H), 1.85 (m, 1H), 2.02 (dd, *J* = 6.9, 8.1 Hz, 1H), 2.29–2.40 (m, 2H), 3.40 (dd, *J* = 4.2, 9.1 Hz, 1H), 3.58 (dd, *J* = 2.2, 6.8 Hz, 1H), 3.70 (d, *J* = 9.2 Hz, 1H), 4.67 (d, *J* = 7.0 Hz, 1H), 4.73 (ddd, *J* = 3.3, 7.1, 7.2 Hz, 1H), 6.10 (s, 1H), 6.40 (br, d, *J* = 7.1 Hz, 1H), 6.91 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 12.6 (3C), 18.0 (6C), 22.0, 33.6, 38.2, 39.9, 44.3, 48.0, 72.6, 75.9, 97.3, 127.5, 129.5, 131.1, 131.3, 133.1, 133.2, 156.0, 162.8; MS (CI) *m/z* 547 (M⁺), 478, 432, 392, 350, 321, 236, 159; HRMS (CI) *m/z* 547.2023 (calcd for C₂₈H₄₁NO₃SiSe: 547.2021).

(1R,1aR,1a'R,3aR,4aR,6R,6bS)-1-Methyl-6-(phenylselenyl)-6a-((trisisopropylsilyloxy)decahydro-1H-4,6-(epimino-methano)dicyclobuta[cd,f]benzofuran-7-one (31). To a solution of **30** (150 mg, 0.275 mmol) in CH₂Cl₂ (10 mL) was added Me₃Al (0.42 mL, 2 M in hexane, 0.824 mmol), and the solution was stirred at 80 °C for 38 h. The solution was diluted with CH₂Cl₂ (30 mL), saturated aqueous potassium tartrate (30 mL) was added, and the mixture was stirred vigorously for 15 min. The separated aqueous phase was extracted with CH₂Cl₂ (3 × 20 mL), and the combined organic solution was dried over MgSO₄. The solvent was removed under vacuum and the residue was chromatographed on silica, using 90% EtOAc in hexane as eluent, to give 104 mg (69%) of **31** as a colorless solid: $[\alpha]_D^{25}$ -8.3 (c 1.8, CHCl₃); IR (neat) 3237 (br), 3067 (br), 2955, 2862, 1677, 1470, 1201, 1147, 1123 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.05 (d, *J* = 7.0 Hz, 3H), 1.13–1.31 (m, 21H), 1.79 (dd, *J* = 7.0, 9.3 Hz, 1H), 2.02–2.20 (m, 3H), 2.84 (m, 1H), 3.02 (m, 1H), 3.69 (dd, *J* = 5.2, 9.2 Hz, 1H), 3.84 (dd, *J* = 5.2, 5.3 Hz, 1H), 3.94 (d, *J* = 9.1 Hz, 1H), 4.02 (dd, *J* = 4.7, 4.8 Hz, 1H), 5.80 (br, s, 1H), 7.18 (m, 3H), 7.60 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 14.6 (3C), 18.7 (Si-Pr), 18.8 (Si-Pr), 22.5, 34.1, 35.2, 36.7, 38.1, 39.6, 41.2, 51.4, 64.9, 76.0, 78.1, 82.5, 127.3, 127.9, 128.4, 135.4, 175.4; MS (CI) *m/z* 547 (M⁺), 478, 432, 390, 322, 276, 251; HRMS (CI) *m/z* 547.2025 (calcd for C₂₈H₄₁NO₃SiSe: 547.2021).

(2aR,2a'R,3R,3aS,4aS,8aR,8bR)-3-Methyl-6-(phenylselenyl)-octahydro-2H-cyclobuta[3,4]benzofuro[7,6-b]pyridine-4,7-(2aH,2a'H)-dione (32 and 33). To a solution of **31** (14 mg, 0.026 mmol) in MeNO₂ (1.9 mL) was added aqueous HF (48%, 0.1 mL), and the solution was stirred at room temperature for 2 h. The mixture was diluted with EtOAc (20 mL), washed with aqueous NaHCO₃ (5 mL) and brine, and dried over MgSO₄. The solvent was removed under vacuum and the residue was chromatographed on silica, using 90% EtOAc in hexanes as eluent, to give 4 mg (40%) of **32** as a colorless oil and 5 mg (50%) of **33** as a colorless oil. **32**: IR (neat) 3184 (br), 3070 (br), 2951, 2934, 2859, 1693, 1660, 1475, 1395 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.18 (d, *J* = 7.1 Hz, 3H), 1.80 (dd, *J* = 5.1, 11.7, 14.2 Hz, 1H), 2.19 (m, 1H), 2.50 (dd, *J* = 8.2, 8.4 Hz, 1H), 2.62 (ddd, *J* = 4.0, 6.9, 7.0 Hz, 1H), 2.83 (ddd, *J* = 3.5, 8.2, 14.1 Hz, 1H), 3.01 (dd, *J* = 4.1, 7.1 Hz, 1H), 3.10 (ddd, *J* = 7.2, 7.3, 8.2 Hz, 1H), 3.58 (dd, *J* = 4.0, 10.8 Hz, 1H), 3.82 (dd, *J* = 3.4, 7.1 Hz, 1H), 3.84 (d, *J* = 10.8 Hz, 1H), 4.01 (dd, *J* = 8.2, 11.0 Hz, 1H), 4.08 (dd, *J* = 3.3, 3.4 Hz, 1H), 7.02 (s, 1H), 7.32 (m, 3H), 7.63 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 21.0, 28.8, 37.1, 37.7, 37.8, 40.3, 44.6, 46.9, 56.6, 72.8, 76.0, 127.6, 128.4, 129.1, 135.4, 172.1, 209.0; MS (CI) *m/z* 390 (M + H), 310, 264, 236, 217, 159; HRMS (CI) *m/z* 390.0766 (calcd for C₁₉H₂₂NO₃⁷⁸Se: 390.0773). **33**: ¹H NMR (300 MHz, CDCl₃) δ 1.24 (d, *J* = 7.1 Hz, 3H), 2.12–2.30 (m, 2H), 2.57 (m, 1H), 2.68 (dd, *J* = 8.2, 8.2 Hz, 1H), 2.79

(ddd, *J* = 5.1, 5.1, 15.6 Hz, 1H), 2.94 (ddd, *J* = 5.0, 5.1, 5.1 Hz, 1H), 3.30 (ddd, *J* = 7.1, 7.1, 7.2 Hz, 1H), 3.60 (dd, *J* = 5.2, 9.8 Hz, 1H), 3.84 (dd, *J* = 4.1, 6.9 Hz, 1H), 3.89 (d, *J* = 9.8 Hz, 1H), 3.99 (dd, *J* = 5.1, 7.1 Hz, 1H), 4.30 (dd, *J* = 4.1, 4.2 Hz, 1H), 6.78 (br, s, 1H), 7.29 (m, 3H), 7.70 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 21.5, 28.2, 37.2, 39.0, 39.6, 40.1, 44.5, 45.6, 55.0, 73.5, 76.4, 128.1, 129.0, 129.9, 134.9, 172.9, 210.9.

(2aR,2a'R,3R,3aS,8bR)-3-Methyl-3,3a,8,8b-tetrahydro-2H-cyclobuta[3,4]benzofuro[7,6-b]pyridine-4,7-(2aH,2a'H)-dione (34). To a solution of **31** (21 mg, 0.037 mmol) in MeNO₂ (10 mL) was added dropwise aqueous HF (48%, 0.06 mL, 0.15 mmol), and the mixture was stirred for 1.5 h at room temperature. The solvent was removed under reduced pressure, and the residue was taken up into MeOH (5 mL) and H₂O (13 mL). To this solution was added a solution of NaO₄ (24 mg, 0.11 mmol) in H₂O (0.2 mL), and the mixture was stirred for 15 h at room temperature. The solvent was removed under reduced pressure, and the residue was taken up into CHCl₃ (20 mL). The solution was washed with saturated NaHCO₃ (2 mL) and brine (5 mL), and the combined aqueous washings were extracted with CHCl₃ (4 × 20 mL). The combined organic extract was dried over MgSO₄, and the solvent was removed under vacuum to leave a residue, which was chromatographed on silica, using 2% MeOH in EtOAc as eluent, to give 7 mg (83%) of **34** as a colorless solid: mp 197–199 °C; $[\alpha]_D^{25}$ -114.8 (c 1.51, CHCl₃); IR (neat) 2958, 1655, 1638, 1408, 1285, 1248; ¹H NMR (300 MHz, CDCl₃) δ 1.30 (d, *J* = 7.0 Hz, 3H), 1.35 (m, 1H), 2.75 (dd, *J* = 8.8, 8.9 Hz, 1H), 2.80 (m, 1H), 3.37 (ddd, *J* = 8.8, 8.8, 8.9 Hz, 1H), 3.57 (dd, *J* = 4.2, 9.0 Hz, 1H), 3.89 (d, *J* = 9.0 Hz, 1H), 4.77 (d, *J* = 8.9 Hz, 1H), 6.60 (d, *J* = 10.7 Hz, 1H), 8.05 (d, *J* = 10.8 Hz, 1H), 12.50 (br, s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 21.2, 37.5, 39.3, 43.3, 46.0, 72.1, 72.2, 114.2, 120.9, 138.6, 151.2, 165.2, 193.1; MS (CI) *m/z* 232 (M + H), 223, 203, 189, 174, 149, 131, 121; HRMS (CI) *m/z* 232.0970 (calcd for C₁₃H₁₄NO₃: 232.0974).

(2aR,2a'R,3R,3aS,8bR)-7-Methoxy-3-methyl-2a',3,3a,8b-tetrahydro-2H-cyclobuta[3,4]benzofuro[7,6-b]pyridine-4(2aH)-one (35). To a solution of **34** (29 mg, 0.126 mmol) in CHCl₃ (2 mL) was added Ag₂CO₃ (173 mg, 0.628 mmol) and MeI (0.47 mL, 7.53 mmol), and the mixture was stirred for 40 h at room temperature. The mixture was filtered through a pad of Celite, which was washed with Et₂O (10 mL), and the filtrate was concentrated under reduced pressure. The residue was chromatographed on silica, using 30% EtOAc in hexanes as eluent, to give 28 mg (91%) of **35** as a colorless solid: mp 100–102 °C; $[\alpha]_D^{25}$ -3.8 (c 2.0, CHCl₃); IR (neat) 2949, 2920, 2857, 1671, 1594, 1484, 1324, 1269 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.35 (d, *J* = 7.0 Hz, 3H), 2.34 (m, 1H), 2.73 (dd, *J* = 8.7, 8.8 Hz, 1H), 2.78 (ddd, *J* = 4.1, 6.8, 7.1 Hz, 1H), 3.32 (dd, *J* = 8.8, 8.8, 8.9 Hz, 1H), 3.68 (dd, *J* = 4.2, 9.2 Hz, 1H), 3.85 (d, *J* = 9.2 Hz, 1H), 4.05 (s, 3H), 4.79 (d, *J* = 7.1 Hz, 1H), 6.80 (d, *J* = 9.1 Hz, 1H), 8.20 (d, *J* = 9.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 21.5, 37.2, 39.0, 43.9, 46.1, 54.2, 71.9, 77.1, 112.4, 122.8, 137.9, 159.0, 166.6, 196.7; MS (CI) *m/z* 246 (M + H), 216, 192, 175; HRMS (CI) *m/z* 246.1127 (calcd for C₁₄H₁₆NO₃: 246.1132).

(5aS,6R,7R,7aR)-7-(Hydroxymethyl)-2-methoxy-6-methyl-6,7,7a,8-tetrahydrocyclobuta[g]quinolin-5(5aH)-one (36). To a solution of **35** (20 mg, 0.082 mmol) in 0.2 M NaOH in MeOH (20 mL) was added activated Zn (0.54 g, 8.2 mmol), and the suspension was stirred for 2 h at 90 °C. An additional quantity (0.54 g) of activated Zn was added to the mixture, which was stirred for a further 4 h at 90 °C. The cooled mixture was neutralized with 1 N HCl in MeOH (4 mL) and was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure and the residue was chromatographed on silica, using 40% EtOAc in hexanes as eluent, to give 19 mg (94%) of **36** as a colorless solid: mp 107–110 °C; IR (neat) 3394 (br), 2916, 2853, 1668, 1625, 1589, 1328 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.11 (d, *J* = 6.9 Hz, 3H), 2.35 (m, 2H), 2.75 (dd, *J* = 8.2, 8.2 Hz, 1H), 3.10 (m, 3H), 3.67 (dd, *J* = 6.9, 11.1 Hz, 1H), 3.73 (dd, *J* = 8.1, 11.2 Hz, 1H), 4.00 (s, 3H), 6.74 (d, *J* = 9.3 Hz, 1H), 8.07 (d, *J* = 9.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 20.8, 29.1, 37.9 (2C), 45.4, 46.7, 53.9, 62.0, 109.8, 123.0, 137.6, 162.8, 166.3, 198.0; MS (CI) *m/z* 248 (M + H), 230, 204, 190; HRMS (CI) *m/z* 248.1284 (calcd for C₁₄H₁₈NO₃: 248.1287).

(5aS,6R,7R,7aR)-2-Methoxy-6-methyl-5-oxo-5,5a,6,7,7a,8-hexahydrocyclobuta[g]quinoline-7-carbaldehyde (37). To a solution of **36** (13 mg, 0.053 mmol) in CH₂Cl₂ (3 mL) was added

Dess–Martin periodinane (38 mg, 0.11 mmol). The solution was stirred for 1 h at room temperature, then was diluted with Et₂O (5 mL), and 10% aqueous Na₂S₂O₃ (2 mL) was added. The mixture was stirred for 20 min, and the aqueous phase was separated and extracted with Et₂O (10 mL). To the combined organic extract was added saturated aqueous NaHCO₃ (5 mL), and the mixture was stirred for 20 min. The separated organic layer was washed with water (3 mL) and brine (3 mL) and was dried over anhydrous MgSO₄. The solvent was removed under vacuum and the residue was chromatographed on silica, using 30% EtOAc in hexanes as eluent, to give 12 mg (93%) of **37** as a colorless oil: IR (neat) 2955, 2925, 1710, 1666, 1590, 1572, 1409, 1321, 1262 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.39 (d, *J* = 6.9 Hz, 3H), 2.80 (dd, *J* = 8.1, 8.1 Hz, 1H), 3.02 (m, 4H), 3.45 (m, 1H), 3.98 (s, 3H), 6.67 (d, *J* = 9.9 Hz, 1H), 8.09 (d, *J* = 9.9 Hz, 1H), 9.80 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 20.6, 29.7, 31.2, 34.5, 46.0, 54.0 (2C), 110.3, 123.0, 137.5, 161.4, 166.5, 196.8, 201.7; MS (CI) *m/z* 246 (M + H), 217, 202, 160; HRMS (CI) *m/z* 246.1126 (calcd for C₁₄H₁₆NO₃: 246.1130).

(5aS,6R,7R,7aR)-7-(1-Hydroxyethyl)-2-methoxy-6-methyl-6,7,7a,8-tetrahydrocyclobuta[g]quinolin-5(5aH)-one (38). To a solution of **37** (25 mg, 0.10 mmol) in CH₂Cl₂ (4 mL) at –78 °C was added dropwise MeMgI (1.5 M in Et₂O, 0.1 mL, 0.15 mmol), and the solution was stirred for 1 h at –78 °C. The reaction was quenched with water, the mixture was allowed to warm to room temperature, and Et₂O (20 mL) was added. The separated ethereal layer was washed with saturated aqueous NaHCO₃ (5 mL) and brine (3 mL) and was dried over anhydrous MgSO₄. The solvent was removed under vacuum and the residue was chromatographed on silica, using 30% EtOAc in hexanes as eluent, to give 9 mg (40%) of **38a** and 8 mg (36%) of **38b** as colorless oils. **38a**: IR (neat) 3408, 2959, 2891, 1650, 1586, 1322, 1269, 1020 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.16 (d, *J* = 6.9 Hz, 3H), 1.10 (d, *J* = 7.0 Hz, 3H), 1.60 (s, 1H), 2.05 (dd, *J* = 9.1, 18.0 Hz, 1H), 2.25 (m, 1H), 2.70 (dd, *J* = 9.2, 9.3 Hz, 1H), 3.10 (m, 2H), 3.25 (dd, *J* = 11.9, 20.2 Hz, 2H), 3.87 (m, 1H), 3.99 (s, 3H), 6.68 (d, *J* = 9.1 Hz, 1H), 8.07 (d, *J* = 9.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 20.9, 21.8, 29.5 (2C), 37.6, 46.2, 51.1, 53.9, 67.6, 109.7, 123.0, 130.9, 137.5, 163.0, 166.3, 198.0; MS (CI) *m/z* 262 (M + H), 244, 228, 175, 146; HRMS (CI) *m/z* 262.1444 (calcd for C₁₅H₂₀NO₃: 262.1443). **38b**: IR (neat) 3457 (br), 2954, 2920, 1669, 1591, 1484, 1415, 1318, 1269 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.22 (d, *J* = 6.9 Hz, 3H), 1.39 (d, *J* = 7.0 Hz, 3H), 1.59 (s, 3H), 2.03 (m, 1H), 2.65 (m, 2H), 2.95 (m, 2H), 3.13 (dd, *J* = 11.8, 20.1 Hz, 2H), 4.00 (m, 1H), 4.01 (s, 3H), 6.64 (d, *J* = 8.8 Hz, 1H), 8.06 (d, *J* = 8.8 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 21.6, 22.8, 29.6, 30.1, 38.9, 46.4, 51.0, 53.9, 68.6, 109.8, 124.3, 137.5, 164.7, 166.7, 197.7; MS (CI) *m/z* 262 (M + H), 244, 228, 204, 175, 146; HRMS (CI) *m/z* 262.1439 (calcd for C₁₅H₂₀NO₃: 262.1443).

(5aS,6R,7R,7aR)-7-Acetyl-2-methoxy-6-methyl-6,7,7a,8-tetrahydrocyclobuta[g]quinolin-5(5aH)-one (39). To a solution of **38** (24 mg, 0.092 mmol) in CH₂Cl₂ (3 mL) was added Dess–Martin periodinane (67 mg, 0.184 mmol), and the solution was stirred for 2 h at room temperature. The solution was diluted with Et₂O (30 mL), 10% aqueous Na₂S₂O₃ (5 mL) was added, and the mixture was stirred for 10 min. The aqueous phase was separated and extracted with Et₂O (10 mL). To the combined organic solution was added saturated aqueous NaHCO₃ (5 mL), and the mixture was stirred for 10 min. The separated organic layer was washed with water (5 mL) and brine (5 mL) and was filtered through anhydrous MgSO₄. The filtrate was concentrated under vacuum and the residue was chromatographed on silica, using 30% EtOAc in hexanes as eluent, to give 22 mg (92%) of **39** as a colorless oil: [α]_D²³ –6.8 (c 1.6 CHCl₃); IR (neat) 2944, 2925, 1704, 1674, 1630, 1591, 1567, 1415, 1327, 1264 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.31 (d, *J* = 6.9 Hz, 3H), 2.15 (s, 3H), 2.70 (dd, *J* = 8.5, 8.6 Hz, 1H), 2.90 (dd, *J* = 10.8, 17.3 Hz, 1H), 3.01 (m, 3H), 3.31 (m, 1H), 3.97 (s, 3H), 6.65 (d, *J* = 9.0 Hz, 1H), 8.07 (d, *J* = 8.9 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 20.3, 29.1, 30.1, 32.0, 35.0, 45.1, 53.9, 54.8, 110.1, 122.8, 137.4, 161.8, 166.3, 196.7, 207.1; MS (CI) *m/z* 260 (M + H), 216, 204, 175, 146; HRMS (CI) *m/z* 260.1287 (calcd for C₁₅H₁₈NO₃: 260.1287).

(5aS,6R,7R,7aR)-2-Methoxy-6-methyl-7-(prop-1-en-2-yl)-6,7,7a,8-tetrahydrocyclobuta[g]quinolin-5(5aH)-one (40). From **39**. To a suspension of dried methyltriphenylphosphonium bromide

(521 mg, 1.46 mmol) in THF (10 mL) under argon at 0 °C was added dropwise *n*-BuLi (0.567 mL, 1.55 M in hexane, 0.878 mmol). The solution was stirred for 1 h then was left to stand for 2 h at 0 °C. To a solution of **39** (25 mg, 0.095 mmol) in THF (7 mL) at –78 °C was added dropwise the supernatant solution of Wittig reagent prepared above (1.77 mL, 0.142 mmol), and the solution was stirred for 1 h at –78 °C. The reaction was quenched with water, the mixture was allowed to warm to room temperature, and Et₂O (20 mL) was added. The separated ethereal layer was washed with saturated aqueous NaHCO₃ (5 mL) and brine (3 mL) and was dried over anhydrous MgSO₄. The solvent was removed under vacuum and the residue was chromatographed on silica, using 5% EtOAc in hexanes and then 15% EtOAc in hexanes as eluent, to give 7 mg (27%, 54% based on recovered **39**) of **40** as a colorless oil: IR (neat) 2948, 2869, 1669, 1591, 1570, 1481, 1410, 1321, 1261 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.31 (d, *J* = 6.9 Hz, 3H), 1.71 (s, 3H), 2.74 (m, 3H), 2.88 (dd, *J* = 8.9, 17.2 Hz, 1H), 3.02 (m, 2H), 4.00 (s, 3H), 4.70 (s, 1H), 4.96 (d, *J* = 1.2 Hz, 1H), 6.64 (dd, *J* = 8.1, 9.0 Hz, 1H), 8.10 (d, *J* = 9.2 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 20.1, 22.2, 29.3, 32.5, 37.7, 46.1, 50.6, 54.3, 110.2, 111.3, 123.0, 137.9, 143.2, 163.8, 166.6, 197.8; MS (CI) *m/z* 257 (M⁺), 242, 228, 190, 175, 163, 149, 135; HRMS (CI) *m/z* 257.1420 (calcd for C₁₆H₁₉NO₂: 257.1416).

From 43. To a solution of **43** (20 mg, 0.051 mmol) in dioxane (2 mL) were added hexamethyldistannane (18 mg, 0.055 mmol), LiCl (7 mg, 0.17 mmol), tetrakis(triphenylphosphine)palladium (3 mg, 0.003 mmol), and a crystal of BHT. The mixture was heated at 90 °C for 4 h, then was cooled to room temperature and treated with pyridine (0.2 mL), followed by a solution of pyridinium fluoride (1.5 M in THF, 0.4 mL). The mixture was stirred for 20 h at room temperature and filtered through Celite. The filtrate was washed with HCl (10%) and brine, dried over anhydrous MgSO₄, and concentrated under reduced pressure. The residue was purified by chromatography on silica as described above to give 11 mg (76%) of **40**.

2-Methoxy-6-methyl-5-methylene-5,5a,6,7,7a,8-hexahydrocyclobuta[g]quinolin-7-yl)ethan-1-one (41). IR (neat) 2957, 2919, 1704, 1594, 1474, 1304, 1262, 1029 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.24 (d, *J* = 6.9 Hz, 3H), 2.10 (s, 3H), 2.68 (m, 2H), 2.80 (m, 2H), 3.05 (m, 1H), 3.91 (s, 1H), 3.97 (m, 1H), 4.94 (dd, *J* = 1.0, 2.0 Hz, 1H), 5.24 (dd, *J* = 1.0, 2.0 Hz, 1H), 6.59 (d, *J* = 9.0 Hz, 1H), 7.63 (d, *J* = 8.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 20.8, 31.9, 34.0, 37.2, 42.1, 53.9, 55.1, 108.2, 109.2, 125.4, 136.0, 144.7, 154.1, 136.6, 208.3; HRMS (CI) *m/z* 258.1494 (calcd for C₁₆H₂₀NO₂: 258.1494).

2-Methoxy-6-methyl-5-methylene-7-(prop-1-en-2-yl)-5,5a,6,7,7a,8-hexahydrocyclobuta[g]quinolone (42). IR (neat) 2949, 2919, 1591, 1475, 1404, 1316, 1259 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, *J* = 6.9 Hz, 3H), 1.71 (s, 3H), 2.39 (m, 3H), 2.60 (dd, *J* = 9.0, 9.0 Hz, 1H), 2.75 (m, 4H), 3.91 (s, 3H), 4.60 (s, 1H), 4.87 (s, 1H), 4.91 (s, 1H), 5.24 (s, 1H), 6.59 (d, *J* = 8.1 Hz, 1H), 7.68 (d, *J* = 8.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 20.1, 22.6, 30.8, 33.9, 42.5, 50.3, 53.9, 107.2, 108.7, 110.4, 124.9, 135.8, 144.1, 145.0, 155.5, 163.5; HRMS (CI) *m/z* 255.1618 (calcd for C₁₇H₂₁NO: 255.1623).

1-((5aS,6R,7R,7aR)-2-Methoxy-6-methyl-5-oxo-5,5a,6,7,7a,8-hexahydrocyclobuta[g]quinolin-7-yl)vinyl Trifluoromethanesulfonate (43). To a solution of **39** (3.3 mg, 0.012 mmol) in THF (4 mL) at –78 °C was added dropwise KHMDS (0.058 mL, 0.5 M in toluene, 0.029 mmol), and the solution was stirred for 30 min at –78 °C. The solution was warmed to 0 °C, a solution of *N*-(5-chloro-2-pyridyl)triflimide (6 mg, 0.015 mmol) in THF (0.5 mL) was added, and the mixture was stirred for 12 h at room temperature. The mixture was diluted with Et₂O (20 mL), water (5 mL) was added, and the phases were separated. The aqueous portion was extracted with Et₂O (2 × 10 mL), and the combined organic extract was washed with brine and was filtered through anhydrous MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by chromatography on silica, using 25% EtOAc in hexanes as eluent, to give 3.1 mg (74%) of **43** as a colorless oil: IR (neat) 2962, 2924, 1669, 1592, 1556, 1418, 1266, 1212, 1142, 913 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.40 (d, *J* = 6.9 Hz, 3H), 2.69 (m, 1H), 2.78 (dd, *J* = 8.8, 10.3 Hz, 1H), 3.10 (m, 4H), 4.00 (s, 3H), 4.99 (dd, *J* = 1.2, 4.8 Hz, 1H), 5.35 (d, *J* = 4.8 Hz, 1H), 6.68 (d, *J* = 9.9 Hz, 1H), 8.10 (d, *J* = 9.9 Hz, 1H); ¹³C NMR (75 MHz,

CDCl_3) δ 19.8, 29.6, 32.2, 38.6, 45.8, 46.8, 54.5, 106.0, 110.7, 123.0, 137.9, 155.2, 162.6, 166.9, 196.6; MS (CI) m/z 392 (M + H), 258, 242, 214, 190, 175, 146; HRMS (CI) m/z 392.0775 (calcd for $\text{C}_{16}\text{H}_{17}\text{F}_3\text{NO}_5\text{S}$: 392.0780).

2-Methoxy-6-methyl-7-(prop-1-en-2-yl)-6,7,8-tetrahydro-cyclobuta[g]quinolin-5(5aH)-one Oxime (44). To a suspension of **40** (3.3 mg, 0.013 mmol) in MeOH (2 mL) was added $\text{NH}_2\text{OH}\cdot\text{HCl}$ (2.2 mg, 0.032 mmol) and $\text{NaOAc}\cdot 3\text{H}_2\text{O}$ (6.1 mg, 0.045 mmol), and the mixture was stirred for 48 h at 85 °C. After cooling to room temperature, the mixture was concentrated under vacuum and the residue was diluted with CHCl_3 (20 mL). The organic solution was washed with brine (5 mL) and was dried over anhydrous MgSO_4 . The solvent was removed under vacuum and the residue was chromatographed on silica, using 10% EtOAc in hexanes as eluent, to give syn and anti isomers of **44** [1.8 mg (51%) of the major isomer and 0.4 mg (12%) of the minor isomer]. Major isomer: IR (neat) 2928, 1596, 1482, 1324, 1256, 1070 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.37 (d, J = 6.9 Hz, 3H), 1.74 (s, 3H), 2.63 (m, 3H), 2.70 (m, 1H), 3.25 (m, 2H), 3.94 (s, 3H), 4.70 (s, 1H), 4.90 (s, 1H), 6.57 (d, J = 9.0 Hz, 1H), 6.92 (br, 1H), 7.95 (d, J = 9.2 Hz, 1H); HRMS (CI) m/z 272.1527 (calcd for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$: 272.1525).

Methyl ((5S,E)-11-Ethylidene-2-methoxy-7-methyl-5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-5-yl)carbamate (46). From **40**. To a solution of **40** (12.0 mg, 0.045 mmol) in benzene (1.5 mL) was added methyl carbamate (4.0 mg, 0.055 mmol) and anhydrous *p*-toluenesulfonic acid (2.0 mg, 0.012 mmol). The solution was heated at 60 °C for 2.5 h, then was cooled to room temperature, washed with HCl (10%), and dried over anhydrous MgSO_4 . The solution was filtered through a pad of Celite, which was washed with Et_2O (3 mL), and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica, using 30% EtOAc in hexane as eluent, to give 4.4 mg (37%) of **46** as a colorless oil: IR (neat) 3325, 1714, 1597, 1529, 1475, 1422, 1322, 1304, 1257, 1034 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.53 (s, 3H), 1.73 (d, J = 1.5 Hz, 3H), 2.25 (d, J = 6.8 Hz, 1H), 2.60 (d, J = 6.4 Hz, 1H), 2.83 (d, J = 6.8 Hz, 1H), 3.07 (d, J = 6.4 Hz, 1H), 3.64 (s, 1H), 3.90 (s, 3H), 5.00 (s, 1H), 5.38 (q, J = 2.2 Hz, 1H), 5.47 (d, J = 1.8 Hz, 1H), 6.57 (J = 6.6 Hz, 1H), 7.58 (d, J = 6.6 Hz, 1H); ^{13}C NMR δ 12.5, 22.6, 33.9, 39.4, 49.1, 51.9, 53.3, 58.7, 108.5, 111.8, 125.6, 130.1, 131.8, 135.4, 136.8, 153.2, 154.8, 162.5; HRMS (CI) m/z 315.1688 (calcd for $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}_3$: 315.1703).

From 1. To a solution of **1** (10 mg, 0.04 mmol) in MeOH (1 mL) at 0 °C was added K_2CO_3 (5.5 mg, 0.06 mmol) and methyl chloroformate (3.3 μL , 4.0 mg, 0.04 mmol). The suspension was stirred for 2 h at room temperature, during which the reaction progress was monitored by TLC (10% MeOH in CH_2Cl_2) until consumption of **1** was complete. The mixture was poured into water and extracted with CH_2Cl_2 (3×10 mL), and the combined extract was washed with brine and dried over MgSO_4 . The solvent was removed under vacuum to provide crude huperzine A methyl carbamate.

To a solution of the crude carbamate obtained above in CHCl_3 (1 mL) were added Ag_2CO_3 (11 mg, 0.04 mmol) and MeI (5 μL , 12 mg, 0.08 mmol). The mixture was stirred at reflux until TLC (40% EtOAc in hexane, 5% MeOH in CH_2Cl_2) indicated complete consumption of the starting material. The mixture was cooled to room temperature and was filtered to remove precipitated solids. The filtrate was concentrated under reduced pressure and the residue was purified by chromatography on silica, using 5–10% EtOAc in hexanes as eluent, to give 4.4 mg of **46** (35%), identical with material prepared from **40**.

(–)-Huperzine A (1). To a solution of **46** (3.0 mg, 10 μmol) in CHCl_3 (0.3 mL) was added slowly TMSI (14 μL , 0.1 mmol), and the mixture was refluxed for 6 h. The solvent was removed under reduced pressure, and the residue was taken up into CH_2Cl_2 (3 mL). The solution was poured into a mixture of saturated aqueous NaHCO_3 and saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$, which was extracted with CH_2Cl_2 (3×5 mL). The combined extract was washed with brine, dried over MgSO_4 , and concentrated under reduced pressure. The residue was purified by chromatography on silica, using 10% MeOH in EtOAc as eluent, to give **1** (2.0 mg, 80%) as a colorless solid: ^1H NMR (CDCl_3) δ 1.28 (br s, 2H), 1.55 (s, 3H), 1.68 (d, J = 6.7 Hz, 3H), 2.11 (d, J = 17.0 Hz, 1H), 2.16 (d, J = 17.0 Hz, 1H), 2.74 (dd, J = 1.5, 16.8 Hz, 1H), 2.90 (dd, J = 5.0, 16.8 Hz,

1H), 3.56–3.65 (m, 1H), 5.41 (d, J = 4.8 Hz, 1H), 5.49 (q, J = 6.7 Hz, 1H), 6.42 (d, J = 9.4 Hz, 1H), 7.91 (d, J = 9.4 Hz, 1H).¹⁷

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b01619.

^1H and ^{13}C NMR spectra of new compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*Tel: 541-737-2173. E-mail: james.white@oregonstate.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We are grateful to Professor Donglu Bai, Shanghai Institute of Materia Medica, for a sample of natural huperzine A, and to the Swiss National Science Foundation for a postdoctoral fellowship (No. PBEZ₂-105115) to M.T. Financial support was provided by the National Institute of General Medical Sciences (Grant No. GM50574) and by the National Science Foundation (Grant No. 0413994-CHE). Support for the Oregon State University NMR facility was provided by the National Science Foundation (Grant No. CHE-0722319) and by the M. J. Murdock Charitable Trust (Grant No. 2005265).

■ REFERENCES

- (1) (a) Woodward, R. B.; Hoffmann, R. *J. Am. Chem. Soc.* **1965**, *87*, 395. (b) Woodward, R. B.; Hoffmann, R. *The Conservation of Orbital Symmetry*; Academic Press: New York, 1970.
- (2) Horspool, W. M. *Aspects of Organic Photochemistry*; Academic Press: London, U.K., 1976.
- (3) For an excellent pedagogical presentation of [2 + 2] cycloaddition in terms of orbital correlation diagrams, see: Carey, F. A.; Sundberg, R. J. *Advanced Organic Chemistry*, 3rd ed.; Plenum Press: New York, 1990; Part A, pp 734–738.
- (4) A more rigorous analysis using correlation diagrams which take account of all orbitals of reactant(s) and product rather than just frontier molecular orbitals has been offered by Longuet-Higgins: Longuet-Higgins, H. C.; Abrahamson, E. W. *J. Am. Chem. Soc.* **1965**, *87*, 2045.
- (5) Crimmins, M. T.; Reinhold, T. L. *Org. React.* **1993**, *44*, 297.
- (6) (a) White, J. D.; Gupta, D. N. *J. Am. Chem. Soc.* **1966**, *88*, 5364. (b) White, J. D.; Gupta, D. N. *J. Am. Chem. Soc.* **1968**, *90*, 6171.
- (7) Schleyer, P. v. R.; Williams, J. E., Jr.; Blanchard, K. R. *J. Am. Chem. Soc.* **1970**, *92*, 2377.
- (8) White, J. D.; Lee, N. C. In *Advances in Strain in Organic Chemistry*; Halton, B., Ed.; Jai Press: Hampton Hill, U.K., 1977; Vol. 6, pp 1–34.
- (9) (a) White, J. D.; Dillon, M. P.; Butlin, R. J. *J. Am. Chem. Soc.* **1992**, *114*, 9673. (b) White, J. D.; Kim, J.; Drapela, N. E. *J. Am. Chem. Soc.* **2000**, *122*, 8665.
- (10) Pirrung, M. C.; Thomson, S. A. *J. Org. Chem.* **1988**, *53*, 227.
- (11) De Mayo, P. *Acc. Chem. Res.* **1971**, *4*, 41.
- (12) (a) White, J. D.; Ihle, D. C. *Org. Lett.* **2006**, *8*, 1081. (b) White, J. D.; Li, Y.; Ihle, D. C. *J. Org. Chem.* **2010**, *75*, 3569. (c) White, J. D.; Li, Y. *Heterocycles* **2014**, *88*, 899.
- (13) After an earlier misassignment, the correct structure of huperzine A was established by confirmation of its identity with the known alkaloid selagine: Ayer, W. A.; Browne, L. M.; Orszanska, H.; Valenta, Z.; Liu, J. S. *Can. J. Chem.* **1989**, *67*, 1538.
- (14) For an account of the history, chemistry, and pharmacology of huperzine A, see: Kozikowski, A. P.; Tuckmantel, W. *Acc. Chem. Res.* **1999**, *32*, 641.
- (15) Xia, Y.; Kozikowski, A. P. *J. Am. Chem. Soc.* **1989**, *111*, 4116.

- (16) Kozikowski, A. P.; Reddy, E. R.; Miller, C. P. *J. Chem. Soc., Perkin Trans. 1* **1990**, 195.
- (17) Yamada, F.; Kozikowski, A. P.; Reddy, E. R.; Pang, Y.-P.; Miller, J. P.; McKinney, M. J. *Am. Chem. Soc.* **1991**, *113*, 4695.
- (18) Qian, L.; Ji, R. *Tetrahedron Lett.* **1989**, *30*, 2089.
- (19) Campiani, G.; Sun, L. Q.; Kozikowski, A. P.; Aagaard, P.; McKinney, M. J. *Org. Chem.* **1993**, *58*, 7660.
- (20) Kaneko, S.; Yoshino, T.; Katoh, T.; Terashima, S. *Tetrahedron* **1998**, *54*, 5471.
- (21) Chassaing, C.; Haudrechy, A.; Langlois, Y. *Tetrahedron Lett.* **1999**, *40*, 8805.
- (22) Koshiba, T.; Yokoshima, S.; Fukuyama, T. *Org. Lett.* **2009**, *11*, 5354.
- (23) Ding, R.; Sun, B.-F.; Lin, G.-Q. *Org. Lett.* **2012**, *14*, 4446.
- (24) Preliminary Communication: White, J. D.; Li, Y.; Kim, J.; Terinek, M. *Org. Lett.* **2013**, *15*, 882.
- (25) Dobbs, A. P.; Guesne, S. J. J.; Parker, R. J.; Skidmore, J.; Stephenson, R. J.; Hursthouse, M. B. *Org. Biomol. Chem.* **2010**, *8*, 1064.
- (26) Eaton, P. E. *Acc. Chem. Res.* **1968**, *1*, 50.
- (27) Crimmins, M. T. *Chem. Rev.* **1988**, *88*, 1453.
- (28) Audia, J. E.; Boisvert, L.; Patten, A. D.; Villalobos, A.; Danishefsky, S. J. *J. Org. Chem.* **1989**, *54*, 3738.
- (29) Hoffmann, N.; Pete, J.-P. In *Chiral Photochemistry*; Inoue, Y., Ramamurthy, V., Eds.; Taylor & Francis: Boca Raton, FL, 2004; p 179.
- (30) Garibaldi, P.; Jommi, G.; Sisti, M. *Gazz. Chim. Ital.* **1986**, *116*, 291.
- (31) Martin, S. F.; Rueger, H.; Williamson, S. A.; Grzejszczak, S. *J. Am. Chem. Soc.* **1987**, *109*, 6124.
- (32) Boger, D. L. *Tetrahedron* **1983**, *39*, 2869.
- (33) Reich, H. J.; Renga, J. M.; Reich, I. L. *J. Org. Chem.* **1974**, *39*, 2133.
- (34) Yadav, J. S.; Barma, D. K. *Tetrahedron* **1996**, *52*, 4457.
- (35) Serckx-Poncin, B.; Hesbain-Frisque, A.-M.; Ghosez, L. *Tetrahedron Lett.* **1982**, *23*, 3261.
- (36) Magnus, P.; Lacour, J. *J. Am. Chem. Soc.* **1992**, *114*, 767.
- (37) Narasaka, K.; Soai, K.; Aikawa, Y.; Mukaiyama, T. *Bull. Chem. Soc. Jpn.* **1976**, *49*, 779.
- (38) Magnus, P.; Rigollier, P.; Lacour, J.; Tobler, H. *J. Am. Chem. Soc.* **1993**, *115*, 12629.
- (39) cf.: Izuhara, T.; Katoh, T. *Org. Lett.* **2001**, *3*, 1653.
- (40) Reich, H. J.; Willis, W. W.; Clark, P. D. *J. Org. Chem.* **1981**, *46*, 2775.
- (41) Bach, T.; Brummerhop, H.; Harms, K. *Chem.—Eur. J.* **2000**, *6*, 3838.
- (42) Newman, M. S.; Evans, S. J., Jr. *J. Am. Chem. Soc.* **1955**, *77*, 946.
- (43) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155.
- (44) Conjugative stabilization of the ketone of **37** through the adjoining methoxypyridine is probably responsible for this selectivity.
- (45) Peterson, D. J. *J. Org. Chem.* **1968**, *33*, 780.
- (46) Petasis, N. A.; Bzowej, E. I. *J. Am. Chem. Soc.* **1990**, *112*, 6392.
- (47) Maercker, A. *Org. React.* **1965**, *14*, 270.
- (48) Comins, D. L.; Dehghani, A. *Tetrahedron Lett.* **1992**, *33*, 6299.
- (49) Farina, V.; Krishnamurthy, V.; Scott, W. J. *Org. React.* **1997**, *50*, 1.
- (50) Tatsumi, T. In *Beckmann Rearrangement*; Sheldon, R. A., Bekkum, H., Eds.; Wiley-VCH: New York, 2001; pp 185–204.